Risultati per: I numeri del cancro in Italia 2019

Objective
People living with HIV (PLWH) are disproportionately affected by substance use disorder (SUD) and mood/anxiety disorders, which are barriers to sustained viral suppression and can contribute to increased healthcare utilisations. This study examined the impact of SUD and mood/anxiety disorders on healthcare utilisation of PLWH with sustained and unsustained viral suppression.

Design and participants
This retrospective population-based cohort study used administrative data from 9757 antiretroviral-treated PLWH (83% men, median age 40 years). Eligible PLWH were≥19 years of age, followed during 2001–2019, and achieved viral suppression at least once during follow-up.

Setting
This study was conducted in British Columbia, Canada.

Measurements
The exposure variable consisted of eight levels and included (1) sustained suppression, (2) SUD and mood/anxiety disorder diagnoses and the interaction between (1) and (2). Outcome variables included annual counts of primary care and specialist physician visits, laboratory visits, acute care hospitalisation, day surgery episodes and hospital length of stay (LOS). Statistical count models were used to determine the effect of exposure variables on each healthcare utilisation outcome while adjusting for socioeconomic confounders.

Results
In the presence of sustained suppression, having both disorders was significantly associated with over four times more acute-care hospitalisations (0.28 vs 0.05), three times longer LOS (9.1 vs 3.0 days) and almost double primary care physician (13.1 vs 6.9) and specialist (7.9 vs 4.0) visits. Overall, SUD alone was associated with increased use of all healthcare services (except day surgery). Regardless of disorder diagnoses, unsustained suppression was associated with higher healthcare utilisation (except day surgery).

Conclusion
In this study, SUD, mood/anxiety disorders and unsustained suppression, when combined, resulted in the highest healthcare utilisation among PLWH. The results suggest that providing comprehensive mental health and substance use services to PLWH and addressing barriers to sustained suppression could reduce the healthcare burden within this population.

Objective
To describe demographics, causative pathogens, hospitalisation, mortality and antimicrobial resistance (AMR) of bacterial bloodstream infections (BSIs) among beneficiaries in the global US Military Health System (MHS), a single-provider healthcare system with 10-year longitudinal follow-up.

Design
Retrospective cohort study.

Setting
Clinical and demographic data collected from the MHS Data Repository and collated with microbiological data obtained from the Defense Centers for Public Health-Portsmouth.
Participants: 12 748 MHS beneficiaries diagnosed with 15 357 bacterial BSIs (2010–2019).

Main outcome(s) and measure(s)
Demographic data and diagnosis codes preceding BSI episodes and during hospitalisations were collected. Inpatient admission data identified acute clinical diagnoses, intensive care unit (ICU) admission and mortality. BSI pathogens were evaluated for AMR, including difficult-to-treat resistance (DTR). Crude mortality trends were assessed.

Results
The decade analysed included 15 357 BSI episodes in 12 748 patients; 6216 patients (48.8%) were≥65 years and 83.7% of episodes had≥1 comorbidity (12 856 of 15 357). Approximately 29% of episodes with hospitalisation required ICU admission and~34% had concurrent urinary tract infections. Pathogen distribution was 53% and 47% for Gram-positive bacteria and Gram-negative bacilli (GNB), respectively. Inpatient mortality was 4.4%, and at 1 year was 23.4%; 0.5% (16 of 2977) of deaths were associated with DTR GNB. Among an average 8 145 778 individuals receiving care annually in the MHS, annual rates of overall BSI, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp and DTR GNB BSI were 18.9, 1.30, 0.25 and 0.05 per 100 000 beneficiaries, respectively. Over the decade, annual mortality did not significantly increase for any pathogen and decreased by~2% for overall BSI (p=0.024) and~3% for lactose-fermenting GNB BSI (p=0.048).

Conclusions
In the global US MHS, the mortality burden associated with BSI was substantial (approximately one in four dying at 1 year), relatively unchanged over a decade, and associated with older age and comorbidities. First-line treatment options remained available for 99.7% of BSIs. Population-level improvements in BSI survival might be maximally influenced by focusing on prevention, early detection, prompt antibiotics and other novel therapies not contingent on in vitro activity.

Problema riguarda anche 1 bimbo su 3, nel mondo 427 milioni

Problema riguarda anche 1 bimbo su 3, nel mondo 427 milioni

Italia dietro anche a Gb, Germania e Francia. Network contro gap

In Europa copertura all’11%, somministrati 15 milioni di vaccini

VII Rapporto Farmacia, forti disparità regionali e generazionali

Esperti, obiettivo dell’innovazione è personalizzare cure e prevenzione

Ai primi test porta sviluppo di cellule immunitarie anti-tumore

Eurostat, Paese a top Ue. Età media salita 4 anni in 2014-2024

Usata soprattutto per dolore cronico, 28 mila pazienti trattati

Si rafforza collaborazione tra Istituti, verso progetti comuni

Palamara (Iss), ‘il virus va ancora monitorato anche senza emergenza’